Suzanne McGurn

President & CEO

Suzanne McGurn is the President and Chief Executive Officer at Canada’s Drug Agency. She leads the organization to deliver credible, objective evidence that helps inform decisions about the best use of drugs and health technologies in Canada.
Suzanne joined the organization in July 2020 and is focused on enabling transformative change that helps support evidence-based health system decision-making.
She spent 17 years working in clinical care as a registered nurse before moving to government. She has held various assistant deputy minister positions within the Ontario public service, focusing on the public drug program and health human resources strategy.
Throughout her career, Suzanne has developed strong relationships with patients, government officials, and industry. Her diverse experience as a clinical and senior leader has provided her with a deep understanding of the complexities in Canada’s health systems.
Suzanne led the implementation of the pan-Canadian Pharmaceutical Alliance (pCPA) and served as its first chair. She is a member of the board of directors at Hospice Quinte and the Victorian Order of Nurses for Canada, as well as a member of the Strategic Advisory Council for MAP Centre for Urban Health Solutions at St. Michael’s Hospital. Suzanne holds a BScN and an MPA from Queen’s University.


All Sessions by Suzanne McGurn

Printer Friendly Download Full Agenda

Day 1 Oct 28, 2025

9:00 am

OPENING KEYNOTE

Engaging with the CDA-AMC Vision for Canada in 2026

Understand the priorities of the CDA-AMC’s expanded role in 2025 and its direction into 2026. Assess the impact of this development on your organization by learning about the existing and emerging core functions of Canada’s Drug Agency. Walk away with an action plan on:

  • Leading national efforts on a pan-Canadian appropriate use and prescribing program.
  • Enhancing patient experience through data and analytics.
  • Improving system coordination across Canada.

Advance your market access strategy with direct guidance from the CDA-AMC to align with national priorities and support equitable access for patients across Canada.

Day 2 Oct 29, 2025